Oramed制药 ORMP 深 沪
已收盘 07-02 16:00:00 美东时间
4.60
-0.010
-0.22%
华盛通- 最 高4.825
- 今 开4.73
- 成交量 36.08万股
- 最 低 4.485
- 昨 收 4.61
- 总市值 1.88亿
- 52周最高 5.19
- 市盈率 静 3.07
- 换手率 0.88%
- 52周最低 1.725
- 委 比 35.38%
- 总股本 4092.61万
- 历史最高 31.48
- 量 比 0.25
- 振 幅 7.38%
- 历史最低 -0.05
- 每 手 1
- 风险率 0.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oramed Pharm Updates Bylaws, Streamlining Shareholder Actions
Oramed Pharm ( ($ORMP) ) has shared an announcement. On June 28, 2026, Oramed P...
07-01 04:52
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and ...
06-17 20:55
Lifeward Closes The Strategic Partnership Agreement With Oramed Pharmaceuticals
Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed
03-26 04:17
Lifeward Successfully Closes on Strategic Partnership with Oramed
Lifeward Ltd. announced the closure of its strategic partnership with Oramed Pharmaceuticals Inc., acquiring Oramed's POD™ technology and securing up to $47 million in capital, with $10 million accessed. The partnership aims to diversify Lifeward's biomedical portfolio and enhance profitability, supporting its mission to innovate for individuals with physical limitations.
03-25 20:10
Lifeward Shareholders Approve Issuance Of Ordinary Shares Over Previously Announced Collaboration Deal With Oramed Pharmaceuticals
Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its
03-13 20:03
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Lifeward Ltd. shareholders approved a strategic partnership with Oramed Pharmaceuticals Inc., integrating Oramed’s POD™ oral delivery technology and accessing up to $47 million in capital. The partnership aims to strengthen Lifeward’s path to profitability while expanding into biotech markets. Lifeward will focus on three core priorities: driving profitability from its MedTech portfolio, selectively investing in innovative technologies, and build...
03-13 12:00
Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal
The latest announcement is out from Oramed Pharm ( ($ORMP) ). On February 19, 2...
02-21 05:53
The top-performing pharma and biotech stocks as group sees resurgence
Pharmaceutical (PJP), (XPH), (PPH) and biotechnology stocks (XBI), (BBH) have officially returned to favor on Wall Street, according to Michael Yee, global head of biotechnology equity research at UBS...
02-14 03:01
UPDATE: Lifeward To Acquire Oramed's POD Technology And Secure Up To $47M Strategic Investment As Oramed Takes Up To 49.99% Stake
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder
01-13 21:18
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward ...
01-13 20:58
